Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2026
Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.
Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02471144 (A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis
Who cites it
3 citing papers in PubMed.
- Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Effectiveness and Safety of IL-17A Inhibitors in Pediatric Psoriasis: A Real-World, Multicenter, International Study.Paediatric drugs · 2026Article
- Long-term safety and efficacy in paediatric psoriasis: Remaining challenges.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPlaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study (NCT02471144), secukinumab treatment for up to 104 weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis.
objectivesFinal long-term safety and efficacy results of secukinumab through 236 weeks of treatment in paediatric patients with severe chronic plaque psoriasis.
methodsDuring the extension period (Weeks 52-236), paediatric patients aged 6 to <18 years with severe chronic plaque psoriasis received either 'Any secukinumab' low dose (LD; patients receiving secukinumab LD up to Week 52; patients on placebo who transitioned to secukinumab LD) or 'Any secukinumab' high dose (HD; patients receiving secukinumab HD up to Week 52 and patients on placebo who transitioned to secukinumab HD). Assessments included Psoriasis Area and Severity Index (PASI) 75/90/100 responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, relapse, rebound, Children's Dermatology Life Quality Index (CDLQI) score, CDLQI 0/1 response and long-term safety up to Week 236.
resultsSecukinumab maintained efficacy through 236 weeks of treatment, with consistent responses observed in most assessments across both dose groups. At Week 236, the responder rate for IGA mod 2011 0/1 was 69.4% ('Any secukinumab' LD) and 79.5% ('Any secukinumab' HD); the PASI 75/90/100 responses were 97.2%/77.8%/50.0% ('Any secukinumab' LD) and 97.4%/84.6%/69.2% ('Any secukinumab' HD). CDLQI 0/1 responses remained consistent in both dose groups and were maintained up to Week 236 ('Any secukinumab' LD: 64.3%; 'Any secukinumab' HD: 67.7%). The most common adverse events were nasopharyngitis (EAIR/100 PYs [95% CI]:13.9 [10.0, 18.7]), headache (5.8 [3.7, 8.8]) and tonsillitis (4.7 [2.8, 7.4]). Candida infections were reported in 3 patients.
conclusionsThese findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236-week treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.